Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) had Normalized Pre-Tax Income of $-13.95M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-13.95M |
|
-- |
|
-- |
|
$14.74M |
|
$-14.74M |
|
$0.79M |
|
$-13.95M |
|
|
Normalized Pre-Tax Income |
$-13.95M |
$-13.95M |
|
$-13.95M |
|
$-13.95M |
|
$-13.95M |
|
$-14.74M |
|
$-14.69M |
|
17.95M |
|
17.95M |
|
$-0.78 |
|
$-0.78 |
|
| Balance Sheet Financials | |
$16.04M |
|
$0.25M |
|
$0.92M |
|
$16.96M |
|
$3.22M |
|
-- |
|
$0.21M |
|
$3.43M |
|
$13.54M |
|
$13.54M |
|
$13.54M |
|
18.86M |
|
| Cash Flow Statement Financials | |
$-15.39M |
|
$2.30M |
|
$9.87M |
|
$9.37M |
|
$6.15M |
|
$-3.22M |
|
$0.62M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.98 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-15.39M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-103.01% |
|
-103.01% |
|
-82.20% |
|
-103.01% |
|
$0.72 |
|
$-0.86 |
|
$-0.86 |
|